About
Company
When our co-founders conceived BSV in the late 90s, they felt that existing consulting firms – even with well-known brand names – lacked the subject expertise and scientific background to really grasp the potential of a life science asset, and to communicate its value accordingly. After all, when it comes to successful fundraising or negotiating a deal, it all comes down to effectively communicating the value of an asset to potential investors or partners. This lies at the core of what we do. We have gathered a highly qualified, interdisciplinary team of experts: our scientists analyze an asset from a molecular and mechanistic perspective, our medical doctors delineate its clinical impact, and our financial mathematicians build intricate models to forecast its sales. The resulting “value story” is robust, defendable, and convincing. Building on the Value Story, we successfully prepare and execute deals, support funding rounds, and offer a large range of other services.
Vision
We strive to be the leading reference in biotech and the life sciences.
Mission
We want to help biotech, pharma, and investment organizations maximize the value of their innovations
– to choose the right indications, close the best deal, and reach the most patients.
Team
Our distinguished team members have left their mark in experimental research at world-class institutions, through leading roles in Biotech and Pharma companies, and in corporate finance, venture capital and investment funds, MedTech, and data science.
Joachim Greuel
PhD, MBA
Co-Founder & Managing Director
Joachim earned his Ph.D. in Physiology 'Summa Cum Laude' from the Max-Planck-Institute for Brain Research in Frankfurt (Germany) and his MBA from the Wharton School of the University of Pennsylvania (USA). At the IE Business School in Madrid (Spain) he served as Academic Director and as Adjunct Professor of Finance and Healthcare Management, teaching the Business School's Pharmacoeconomics course. Besides, he is a certified stock broker / dealer (Frankfurt Stock Exchange).
Joachim began his professional career as head of a research team at Bayer AG (Germany). After his business education he joined the strategic services practice of Andersen Consulting (Switzerland and Germany). Before founding Bioscience Valuation Joachim was investment manager at New Medical Technologies, a Swiss venture capital fund.
Joachim Greuel
PhD, MBA
Co-Founder & Managing Director
Kerstin Bode-Greuel
MD, PhD
Co-Founder & Managing Director
Kerstin studied Medicine in Marburg (Germany), Cambridge (UK) and Nottingham (UK). She started her professional career with a doctoral thesis in Neuroanatomy followed by a postdoc in Neurophysiology and Neuropharmacology at the Max-Planck-Institute for Brain Research (Frankfurt am Main, Germany). Subsequently Kerstin spent eight years at Bayer AG, holding several roles in R&D and responsibility as Global Program Manager for a clinical-stage product that has been developed in six indications. During that time she was also part of a corporate task force implementing value-driven portfolio management. Since 1995 Kerstin has been working as a consultant for the Pharma and Biotech industry. She was educated in Corporate Finance at the Wharton School of the University of Pennsylvania (USA) and developed and enhanced modern, quantitative project and portfolio management methods.
With the goal to expand her experience in evidence-based valuation taking advantage of patient-centric data, Kerstin worked for IQVIA 2012-2019. She developed new offerings for patient-based real world data and was Director of Business Development for Germany. During that time, she was also Managing Director of a Joint Venture between IQVIA and the Deutsches Institut for fachärztliche Versorgungsforschung, DIFA.
Kerstin Bode-Greuel
MD, PhD
Co-Founder &
Managing Director
Merlin Greuel
MD, MGH
Director
Merlin holds a BA in Psychology with a Minor in Latin American Studies from Stanford University (USA), a Master of Global Health from the University of Barcelona (Spain), and an MD from Heidelberg University (Germany). He also studied at the Stanford Center in Santiago (Chile), the University of Seville (Spain), and completed part of his clinical training in Milan (Italy).
Merlin has diverse, interdisciplinary, and global experience in the healthcare sector. Born with a natural interest in science, he began exploring the business side of biotech at the age of 17 when he performed his first financial analysis of Genentech. While in college, collaborations with nonprofits in Colombia, Mexico, and Bolivia stimulated his interest in global health, a field in which he conducts research to this day. Merlin has worked for BSV since 2013 (full-time since 2021) and lives in Veneto (Italy).
Merlin Greuel
MD, MGH
Director
Philipp Steinbach
MS
Director
Lead Financial Analysis
Philipp studied Business Administration at the Frankfurt School of Finance & Management (Germany) and at the University College Dublin (Ireland) with a focus on financial mathematics, financial modelling, and international & corporate finance. In parallel to his Bachelor studies he worked at the Landesbank Hessen Thüringen in the fixed income trading sector.
After his Bachelor's degree Philipp did his Master's degree in Finance at the Leopold-Franzens University in Innsbruck (Austria) with a specialization in corporate evaluation. Philipp's responsibilities include financial modelling, portfolio assessments, as well as deal term valuations.
Philipp Steinbach
MS
Director
Lead Financial Analysis
Qianyu Gu
MD, PhD
Healthcare Analyst
Qianyu obtained her MD at Hebei Medical University (Shijiazhuang, China), with a focus on thoracic surgery of lung and esophageal cancers. She supported a Phase IV clinical trial to gather post-marketing data on a traditional Chinese medicine (TCM) product as part of her thesis. She also completed some of her clinical training in Shjiazhuang (China).
Subsequently, Qianyu pursued a Dr.med. (Ph.D.-equivalent in Germany) at the Carl Gustav Carus University Hospital (Dresden, Germany), focusing on the role of extracellular vesicles (EVs) in colorectal cancer. She was responsible for developing an experimental method of extracellular treatment on cells, investigating the presence of biologically “active” EVs in the serum of a large cohort of patients. Qianyu successfully identified potential candidates for a gene signature to improve the diagnosis and prediction of clinical outcomes in CRC patients.
Qianyu Gu
MD, PhD
Healthcare Analyst
Luna Benitez-Requena
MS, MS
Senior Healthcare Analyst
Luna holds a BS in Chemistry and Biochemistry, an MS in Biology, and an MS in Evolution, Ecology, and Systematics, all obtained from Ludwig Maximilian University of Munich (Germany). During her academic career, she learned to integrate her skills in laboratory experiments, field work, and data management, enabling her to work across various disciplines. She gained experience as a scientist at the Max-von-Pettenkofer-Insitute (virology), the Helmholtz-Zentrum (virology), and the Max-Planck-Institute for Biochemistry (molecular medicine).
Luna grew up both in Spain and Germany and speaks Spanish, German, and English fluently. She joined the BSV team in 2022.
Luna Benitez-Requena
MS, MS
Senior Healthcare Analyst
Frithjof Sy
MD, MS, BS
Healthcare Analyst
Frithjof studied physics at the Technical University Munich (TUM, Germany) and specialized in fusion physics at the Max Planck Institute for Plasma Physics in Garching (Germany). After his BS, he focused on medical applications in physics (e.g. MRI and CT technology). He is currently completing a Master’s degree in Biomedical Engineering and Medical Physics at TUM, exploring topics in mathematical oncology and clinical artificial intelligence in cooperation with RWTH Aachen, NCT Heidelberg, and TU Dresden.
In addition, Frithjof obtained an MD with a focus on oncology and infectious diseases from Heidelberg University (Germany). He is in the final stages of his doctoral thesis at the Heidelberg Institute of Global Health, with publications in high-ranking journals. He conducted research on human papillomavirus infections and cervical cancer. Moreover, he worked and studied abroad with stops in Oslo (Norway) and different sub-Saharan African countries. Frithjof joined the BSV team in 2022.
Frithjof Sy
MD, MS, BS
Senior Healthcare Analyst
Selina Greuel
MD, PhD, MBA
Director
Selina obtained her MD at the Charité – University Hospital Berlin, with a focus on oncology, and palliative and rehabilitation medicine. She started her professional career at the Berlin Institute of Health (BIH) Center for Regenerative Therapies with a doctoral thesis on the expansion and differentiation of human induced pluripotent stem cells (hiPSCs) for extracorporeal liver support (‘summa cum laude’).
Subsequently, Selina worked as an assistant physician at the Institute of Pathology at the Charité University Hospital; she was responsible for most COVID-19 autopsies and investigated causes of death in COVID-19 decedents as well as SARS-CoV-2 pathophysiological mechanisms, leading to publications in high-ranking journals.
Selina Greuel
MD, PhD, MBA
Director
Michael Ruppert
PhD, MBA
Lead Client Business Development
Michael is an internationally networked business development executive with an extensive operational, commercial, licensing, and R&D background in pharma and biotech companies. With more than 25 years of experience in the pharmaceutical industry, his track record of executing large collaborations and transactions is outstanding.
Michael has worked for numerous pharma and biotech clients with a focus on business development and licensing, including Sandoz, Mundipharma, Hikma, Polpharma, and MediGene. He holds a Master’s degree in Biology from Heidelberg University, a PhD in Molecular Biology from the German Cancer Research Center (DKFZ), and an MBA from Henley Management College in the UK.
Michael Ruppert
PhD, MBA
Lead Client Business Development
Michael Kapfer
BSc
Data & Operation Manager
Michael holds a B.Sc. in Biology from the University of Regensburg and completed his bachelor's thesis on hyperthermophilic bacteria and their use for industrial purposes. He gained first-hand industry experiences in a microbiology lab. Besides his life science education, he completed coursework in programming and web design.
